Nicotine effects on associative learning in human non-smokers.

What Was Tested

This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).

Nicotine is considered the primary constituent responsible for tobacco addiction.

Its paradoxically high abuse potential may reflect behavioral control by drug-associated stimuli, which appears to play a larger role for tobacco dependence than for other abused drugs.

Who Took Part

By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Therapeutic nicotine (patch, non-peptide), giving a reference point.

In the crossover set-up each of the participants took both Therapeutic nicotine (patch, non-peptide) and the comparison in turn, acting as their own control.

What Was Measured

Nicotine is considered the primary constituent responsible for tobacco addiction.

The researchers tested a potential explanation, hypothesizing that nicotine enhances associative learning, the mechanism underlying the conditioning of drug-associated stimuli.

The subject headings attached to it are Association Learning, Nicotine, Nicotinic Agonists, Non-Smokers, Photic Stimulation, Reaction Time and Tobacco Use Cessation Devices.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

The publication is from 2018 (Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.